How many 8-K filings has Theravance Biopharma, Inc. filed?

Theravance Biopharma, Inc. (TBPH) has 21 8-K (Current Event Report) filings on record, spanning Jan 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Theravance Biopharma, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Theravance Biopharma, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Theravance Biopharma, Inc. (TBPH) — 8-K Filings

All 8-K filings from Theravance Biopharma, Inc.. Browse 21 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (21)

Theravance Biopharma Files 8-K Report — Dec 8, 2025 Risk: low
On December 8, 2025, Theravance Biopharma, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." Speci
Theravance Biopharma Files 8-K on Financials — Nov 10, 2025 Risk: low
Theravance Biopharma, Inc. filed an 8-K on November 10, 2025, to report on its results of operations and financial condition. The filing also includes financial
Theravance Biopharma Files 8-K: Other Events & Exhibits — Aug 25, 2025 Risk: low
On August 25, 2025, Theravance Biopharma, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specif
Theravance Biopharma Files 8-K: Other Event Reported — Aug 20, 2025 Risk: low
On August 15, 2025, Theravance Biopharma, Inc. filed an 8-K report detailing an "Other Event." The filing does not contain specific financial figures or signifi
Theravance Biopharma Files 8-K on Operations — Aug 12, 2025 Risk: low
Theravance Biopharma, Inc. filed an 8-K on August 12, 2025, to report on its results of operations and financial condition. The filing also includes financial s
Theravance Biopharma Files 8-K Report — Jun 26, 2025 Risk: low
On June 10, 2025, Theravance Biopharma, Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in the Cayman Island
Theravance Biopharma Files 8-K for Other Events — Jun 6, 2025 Risk: low
On June 5, 2025, Theravance Biopharma, Inc. filed an 8-K report. The filing pertains to "Other Events" and does not disclose specific financial transactions or
Royalty Pharma Acquires Theravance Biopharma — Jun 2, 2025 Risk: medium
On May 30, 2025, Theravance Biopharma, Inc. announced the completion of its acquisition by Royalty Pharma plc. The transaction was previously announced on March
Theravance Biopharma Files 8-K on Shareholder Vote Matters — May 20, 2025 Risk: low
Theravance Biopharma, Inc. filed an 8-K on May 20, 2025, reporting on a submission of matters to a vote of security holders. The filing date for the report is M
Theravance Biopharma Files 8-K on Financials — May 8, 2025 Risk: low
Theravance Biopharma, Inc. filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition. The filing includes financial statements
Theravance Biopharma Files 8-K on Financials — Feb 26, 2025 Risk: low
Theravance Biopharma, Inc. filed an 8-K on February 26, 2025, reporting on its results of operations and financial condition. The filing also includes financial
Theravance Biopharma Files 8-K on Operations and Financials — Nov 12, 2024 Risk: low
Theravance Biopharma, Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition, as well as filing financial statem
Royalty Pharma to Acquire Theravance Biopharma for $1/Share — Sep 23, 2024 Risk: low
Theravance Biopharma, Inc. announced on September 18, 2024, that it has entered into a definitive agreement to be acquired by Royalty Pharma plc for $1.00 per s
8-K Filing — Sep 10, 2024
Theravance Biopharma Files 8-K on Financials — Aug 5, 2024 Risk: low
Theravance Biopharma, Inc. filed an 8-K on August 5, 2024, to report on its results of operations and financial condition. The filing also includes financial st
Theravance Biopharma Files 8-K on Financials — May 13, 2024 Risk: low
Theravance Biopharma, Inc. filed an 8-K on May 13, 2024, reporting on its results of operations and financial condition. The filing includes financial statement
Theravance Biopharma Files 8-K on Shareholder Vote Matters — May 9, 2024 Risk: low
Theravance Biopharma, Inc. filed an 8-K on May 8, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific d
Theravance Biopharma Files 8-K for 'Other Events' — Feb 28, 2024 Risk: medium
Theravance Biopharma, Inc. filed an 8-K on February 28, 2024, under the 'Other Events' category. The filing indicates a current report pursuant to Section 13 or
Theravance Biopharma Files 8-K on Financial Condition — Feb 26, 2024 Risk: low
Theravance Biopharma, Inc. filed an 8-K on February 26, 2024, to report on its results of operations and financial condition. The filing indicates the company's
Theravance Biopharma 8-K Confirms NASDAQ Listing, No New Material Events — Jan 16, 2024
Theravance Biopharma, Inc. filed an 8-K on January 12, 2024, under the 'Other Events' category, indicating no specific new material event but rather a routine f
TBPH Files 8-K for 'Other Events' and Financial Exhibits — Jan 5, 2024
Theravance Biopharma, Inc. (TBPH) filed an 8-K on January 5, 2024, to report an "Other Event" and "Financial Statements and Exhibits." This filing indicates tha

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX